Cardiorenal and mortality benefits reported for SGLT2i and GLP-1 RA.aSGLT2i. CVOTs for empagliflozin, canagliflozin, dapagliflozin and ertugliflozin have all pointed to beneficial effects on HHF and renal function outcomes [2,3,4,5,7,11,13], either in a population with T2D and established C...
Newer classes of glucose-lowering agents (GLAs), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is), have been shown to improve liver-related biomarkers. However, their effects on the development of NAFLD/NASH remain inconclusive....
Cardiorenal and mortality benefits reported for SGLT2i and GLP-1 RA.aSGLT2i. CVOTs for empagliflozin, canagliflozin, dapagliflozin and ertugliflozin have all pointed to beneficial effects on HHF and renal function outcomes [2,3,4,5,7,11,13], either in a population with T2D and established C...
DKA has been observed in T2D patients taking Glucagon-Like Peptide 1 Receptor (GLP-1) agonists and Dipeptidyl peptidase-4 (DPP-4) inhibitors9,10. However, the risk of DKA with SGLT2i is two to three times more than other oral T2D medications4,10. EuDKA is a relatively new phenomenon ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a reliable hypoglycaemic and weight-loss effect that can intervene in obesity, which is the basis of type 2 diabetes pathology. GLP-1RA therapy has shown potential benefits in reducing the risk of major adverse cardiovascular events and ...
A sensitivity and subgroup analyses were performed according to the class of diabetes medication. Results: A total of 9 trials (GLP-1RA in 6 trials and SGLT-2i in 3) were included. Of the 84,258 participants enrolled, 30,784 (37%) participants were women. Pooled results showed a ...
Mounjaro结构畅销原因:tizepatide是首个双作用葡萄糖依赖性胰岛素性多肽(GIP)和GLP-1受体激动剂,被批准用于治疗2型糖尿病。它以GIP受体为靶点,补充GLP-1的作用,改善胰岛素调节和血糖控制。2023年11月,FDA还批准了tizepatide(Zepbound)用于成人肥胖患者的慢性体重管理。 07 NovoRapid TOP7:NovoRapid(Insulin Aspart,...
symptoms of heart failure, quality of life and reduce the chance of people with heart failure being admitted to hospital or dying. However, people with type 1 diabetes and heart failure were not included in these trials meaning that it is not known if these benefits also apply to this ...
(DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors. Whereas a variety of conventional antidiabetic drugs have been shown to retard the progression of nephropathy through glycemic control [1], there are a limited number of ...
Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment: Patients with type 1 diabetes mellitus (T1DM) may have suboptimal glucose control and are interested in the use of adjuvant therapies.#To...